Compass Therapeutics (CMPX) Other Accumulated Expenses (2019 - 2026)
Compass Therapeutics (CMPX) posted Other Accumulated Expenses of $708000.0 for Q1 2026, up 46.28% sequentially from $484000.0 in Q4 2025, and up 158.39% YoY from $274000.0 in Q1 2025.
Compass Therapeutics (CMPX) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
Compass Therapeutics has reported Other Accumulated Expenses for 8 years, with the latest figure at $708000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 158.39% year-over-year to $708000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $708000.0 (up 158.39% YoY) and the FY2025 annual result came in at $484000.0, down 22.06% from the prior year.
- Other Accumulated Expenses improved to $708000.0 in Q1 2026 per CMPX's latest filing, from $484000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.5 million in Q1 2022 and troughed at $88000.0 in Q3 2022.
- A 5-year average of $372470.6 and a median of $281000.0 in 2024 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses soared 481.35% in 2022, then sank 90.65% in 2023.
- Over 5 years, Other Accumulated Expenses stood at $96000.0 in 2022, then soared by 150.0% to $240000.0 in 2023, then jumped by 158.75% to $621000.0 in 2024, then dropped by 22.06% to $484000.0 in 2025, then surged by 46.28% to $708000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $708000.0, $484000.0, and $141000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 708,000.00 |
| Dec 31, 2025 | 484,000.00 |
| Sep 30, 2025 | 141,000.00 |
| Jun 30, 2025 | 384,000.00 |
| Mar 31, 2025 | 274,000.00 |
| Dec 31, 2024 | 621,000.00 |
| Sep 30, 2024 | 167,000.00 |
| Jun 30, 2024 | 308,000.00 |
| Mar 31, 2024 | 281,000.00 |
| Dec 31, 2023 | 240,000.00 |
| Sep 30, 2023 | 391,000.00 |
| Jun 30, 2023 | 255,000.00 |
| Mar 31, 2023 | 137,000.00 |
| Dec 31, 2022 | 96,000.00 |
| Sep 30, 2022 | 88,000.00 |
| Jun 30, 2022 | 292,000.00 |
| Mar 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 470,000.00 |
| Sep 30, 2021 | 734,000.00 |